Drug updates and approvals: 2018 in review.

Autor: Mospan C; Cortney Mospan is an assistant professor of pharmacy at Wingate University, Levine College of Health Sciences, Wingate, N.C. Geoffrey Mospan is an assistant professor of pharmacy at Wingate University, Levine College of Health Sciences, Wingate, N.C. Emily Byland is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. William Blake Whitaker is a PharmD candidate at Wingate University, School of Pharmacy, Hendersonville, N.C. Linda Xiong is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. Jordan Dunlap is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. Katherine Canupp is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C., Mospan G, Byland E, Whitaker WB, Xiong L, Dunlap J, Canupp K
Jazyk: angličtina
Zdroj: The Nurse practitioner [Nurse Pract] 2018 Dec; Vol. 43 (12), pp. 23-32.
DOI: 10.1097/01.NPR.0000547548.63764.6b
Abstrakt: In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).
Databáze: MEDLINE